奈达铂、紫杉醇联合同期放疗治疗中晚期宫颈癌的可行性研究

Feasibility of nedaplatin and paclitaxel combined with concurrent radiotherapy in the treatment of advanced cervical cancer

目的 探讨奈达铂、紫杉醇联合同期放疗治疗中晚期宫颈癌的可行性.方法 选取2015年4月~2017年3月我院收治的90例中晚期宫颈癌患者,随机分为对照组(n=43,常规放疗)与试验组(n=47,奈达铂、紫杉醇联合同期放疗),观察两组患者的肿瘤缓解情况、随访1年与随访2年的生存情况及复发转移情况、毒副反应发生情况与不良反应发生情况.结果 试验组的总缓解率与生存率明显较高,复发转移率明显较低,毒副反应发生率明显较高,不良反应发生率明显较高,与对照组比较差异有统计学意义(P<0.05).结论 ?奈达铂、紫杉醇联合同期放疗治疗中晚期宫颈癌具有较大的可行性,能够提升肿瘤总缓解率与生存率,但将降低复发率.

Objective To investigate the feasibility of nedaplatin and paclitaxel combined with concurrent radiotherapy in the treatment of advanced cervical cancer.Methods 90 patients with advanced cervical cancer treated in our hospital from April 2015 to March 2017 were randomly divided into control group(n=43,routine radiation)and study group(n=47,nedaplatin and paclitaxel combined with concurrent radiation).The tumor response was observed in both groups,and the survival,recurrence and metastasis,toxic side effects and adverse reactions in the two groups of patients during 1 year and 2 years of follow-up were observed.Results As compared with the control group,the total remission rate and survival rate of the study group were significantly higher,the recurrence and metastasis rate were significantly lower,the incidence of toxic side effects and adverse reactions were significantly higher,and the differences were statistically significant(P<0.05).Conclusion Nedaplatin and paclitaxel combined with concurrent radiotherapy are feasible in the treatment of advanced cervical cancer,which can improve the overall remission rate and survival rate,and reduce the recurrence rate.